X

Trial Profile

Effect of subcutaneous semaglutide 2.4 mg once-weekly compared to placebo in subjects with obesity and knee osteoarthritis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semaglutide (Primary)
Indications Obesity; Osteoarthritis
Focus Registrational; Therapeutic Use
Acronyms STEP-9
Sponsors Novo Nordisk

Most Recent Events

23 Feb 2024 This study has been Completed in Norway, According to European Clinical Trials Database record.
13 Sep 2023 Status changed from active, no longer recruiting to completed.
10 Nov 2022 Planned primary completion date changed from 25 Apr 2023 to 18 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com